Navigation Links
BRCA test results affect patients' breast cancer surgery plans

PROVIDENCE, R.I. [Brown University] Women diagnosed with breast cancer often face a crucial decision about the extent of their surgical treatment. Many meet national guidelines recommending testing for mutations in the BRCA 1 and 2 genes, which carry a substantial risk of future cancer. A new study reports that among women with breast cancer who undergo recommended testing before surgery, more than 7 in 10 who test positive will change their surgical plan, typically opting for a more extensive procedure such as a double mastectomy and sometimes ovary removal.

"As soon as somebody hears they have a 65 percent chance of a new breast cancer in the future or an up to 60 percent chance of ovarian cancer, they are likely to do whatever they can to prevent that," said lead author Dr. Elizabeth Lokich, an obstetrics and gynecology fellow in the Warren Alpert Medical School of Brown University and at Women & Infants Hospital.

The study appears online in the journal Gynecological Oncology with the recommendation that women who meet National Comprehensive Cancer Network guidelines for genetic testing get the test before deciding on their surgery.

"Particularly because of what we found that it changes their surgical planning it really makes the most sense to have this evaluation done pre-operatively," Lokich said.

The study was based on a retrospective review of the records of 302 Women & Infants breast cancer patients who had undergone preoperative genetic testing between 2006 and 2012 because they met the NCCN guidelines. Within that group, 32 learned that they carried a mutation in their BRCA1 or BRCA2 genes. With that information, 71.9 percent, or 23, of the women who tested positive changed their surgical plan compared to only 28.9 percent of women who tested negative.

Among the mutation carriers, 31.3 percent chose lumpectomies, while 59.4 percent chose double mastectomies and one in eight chose ovary removal. Among women who tested negative, 58.5 percent chose lumpectomies, only 20.7 percent chose double mastectomy and none elected to have their ovaries removed.

Stress and timing

Many women who meet the guidelines do not have a preoperative genetic test, even though it can provide important information. The effect of a positive BRCA mutation test on surgical decision-making had not been studied before and doctors have debated what the best timing should be. Some have argued that testing would add too much stress at a time when women are already coping with learning of their serious diagnosis. Indeed, Lokich acknowledged, some women choose not to be tested.

But Lokich said other studies suggest that genetic testing doesn't add much stress overall.

Instead, the likely reason most women in the study who tested positive for BRCA mutation often changed their surgery plan from lumpectomy to double mastectomy was to prevent a second bout of breast cancer or ovarian cancer.

In the study Lokich and her colleagues found that genetic testing significantly delayed getting to surgery, but not by enough to postpone it past the 90 days post-diagnosis that studies have shown to be clinically significant.

The authors therefore concluded, "We recommend that women meeting NCCN referral guidelines have their genetic evaluation done prior to surgical intervention."

Contact: David Orenstein
Brown University

Related medicine news :

1. New therapy for pancreatic cancer patients shows promising results
2. Long-term results encouraging for combination immunotherapy for advanced melanoma
3. Immune therapy for advanced bladder cancer yields promising results
4. EORTC to present cancer research results at ASCO 2014
5. Clinicians urged to consider spironolactone in HFPEF despite TOPCAT results
6. Ataluren Phase 3 trial results in nonsense mutation cystic fibrosis
7. Vibrating capsule shows promising results in treating chronic constipation
8. Automated link to national intervention guidance helps doctors interpret FRAX results
9. Real-world heart procedure results consistent with scientific research
10. Resin infiltration effects in a caries-active environment -- 2 year results
11. Reducing RT dose to bilateral IB lymph nodes results in better patient-reported salivary function
Post Your Comments:
Related Image:
BRCA test results affect patients' breast cancer surgery plans
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. (BSI) ... for the Nutraceutical Specialties products into oral solid dosage in the over the ... “We are pleased to announce our expanded distribution agreement with ASI.” said Steve ...
(Date:11/30/2015)... ... November 30, 2015 , ... An inventor from Charlottesville, Va., is ... "My last baby had high blood pressure due to loud noises," she said, "so ... babies from noise pollution as well as radio waves and microwaves." , The baby ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its ... specializing in independent living, assisted living and all other retirement options. Support for ... awareness and research remains a top priority. , So it’s no surprise ...
(Date:11/30/2015)... New York, New York (PRWEB) , ... November 30, 2015 , ... ... at the Greater New York Dental Meeting. Their Ecosystem empowers dentists to make complex ... Dentists who visit the booth will receive a free fee survey with 10 procedures ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... of DataTrade Solutions Inc., a Healthcare IT consulting, development and support company. The ... and technical experience available within DataTrade to extend the services currently provided by ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... , Nov. 30, 2015   Nuance Communications, Inc. ... National Decision Support Company (NDSC) today jointly announced ... collaboration capabilities that utilize the American College of Radiology,s ... provider organizations to comply with current and emerging ... --> By combining clinical decision support, ...
(Date:11/30/2015)... , Nov. 30, 2015  Novartis will demonstrate the ... 57 th American Society of Hematology (ASH) Annual ... myelomas as well as supportive care, including key findings ... personalized cell therapies. The ASH Annual Meeting will be ... . Novartis Oncology . "We will be ...
(Date:11/30/2015)... Israel , Nov. 30, 2015  OticPharma, Ltd., ... and developing innovative therapies for ear, nose, and throat ... A. Katkin as chairman of the company,s board ... executive officer for OticPharma, Ltd.  "Keith brings a wealth ... will be able to share this experience and provide ...
Breaking Medicine Technology: